During December 2007, WHO delegate Alejandro Costa introduced WHO's evaluation project on Meningococcal vaccine production capacities.
Despite of an increasing demand of Meningococcal vaccine in developing countries the world faces shortcomings in the supply of Meningococcal vaccine due to shrinking of production capacities.
Mr Alejandro Costa held discussions with Tianyuan colleagues and gave some suggestions and opinions on the meningococcal production facility. With the stop production of meningococcal vaccine of large foreign companies stops to produce this vaccine while the increasing demand in developing countries, our meningococcal vaccine manufacturing has a promising outlook, so the WHO pre-qualification process has a critical significance.
From now on, we shall begin to prepare it, to set up facility with EU standard, establish document complying with national standard, make qualification and validation, etc.
Meningococcal Polysaccharide Vaccine
Meningococcal meningitis caused by the bacterium Neisseria meningitides, is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain and can result in brain damage and even death.
The bacteria are spread by direct close contact with the discharges from the nose or throat of an infected person.
Meningococcal meningitis is most common in infants and children. People who have had close or prolonged contact with a patient with meningococcal meningitis are at increased risk.
Bacterial meningitis can be treated with antibiotics, but an early diagnosis and treatment is crucial.
To prevent the disease, vaccines are the best choice.
Tianyuan is currently establishing its new bacterial vaccine facility and plans to bring its divalent (AC) and quadrivalent (ACYW135) meningococcal polysaccharide vaccines to market in 2008.
Tianyuan aspires to get the WHO-prequalification for its vaccines.